Loading…
← CockpitCompetitor Analysis › SUPN Supernus Pharmaceuticals, Inc.Open in the cockpit ↗

Supernus Pharmaceuticals, Inc.SUPNCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

CNS specialty pharma selling epilepsy, ADHD and Parkinson's drugs including Qelbree and Trokendi XR.

Momentum laggard 10
Mkt cap
$6.02B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$105M
20-day average traded
Fwd P/E
8.0×
forward earnings
ROIC−WACC
n/a
WACC 9.7%
Hurdle
-8 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · USD$28.96
1D-0.3%
1W-1.7%
1M-29.8%
3M-39.0%
6M-40.5%
YTD-41.7%
1Y-35.8%
ATR %6.8%
Beta0.76
52w lowhigh51.5% off high

What Supernus Pharmaceuticals does

CNS specialty pharma selling epilepsy, ADHD and Parkinson's drugs including Qelbree and Trokendi XR.

Sells branded prescription drugs in the US through its own sales force, with reported sales net of rebates paid to insurers and pharmacy middlemen. Its older epilepsy products are mature and exposed to generic copies, so growth rests on newer drugs. It bought Sage Therapeutics in 2025, adding a postpartum depression drug sold through a Biogen partnership.

Products and services

  • Qelbree (ADHD)
  • Trokendi XR / Oxtellar XR (epilepsy)
  • Onapgo (Parkinson's)

Customers

  • Neurologists/psychiatrists
  • Pediatricians

Where it sits in the supply chain

  • CNS pharmaceuticals
  • Extended-release neurology drug…
  • Specialty pediatric/adult CNS sales

What could go right

  • Qelbree prescription growth
  • Onapgo Parkinson's launch ramp

What could go wrong

  • Core epilepsy franchise facing generic erosion
  • Reimbursement pressure on branded CNS drugs

Moat: narrow (IP / patents, distribution). Extended-release formulation patents and an established CNS sales force protect share.

Headquarters: Rockville, Maryland, US · Founded: 2005 · Employees: 838

Named competitors

Supernus Pharmaceuticals at a glance

Size Supernus Pharmaceuticals (SUPN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.02B, the 1054th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.96 on 18 Nov 2026.

Performance Over six months the shares fell 40.5%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 16.4% over the last twelve months (peer median +11.6%); the operating margin is 45.0% (peer median 17.2%).

Valuation It trades at 8.0× forward earnings against a peer median of 24.4× (2nd cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -8 pp: the price already allows for a slowdown.

Short interest Short interest is 3.7% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 99SUPN 59
Six months, rebased to 100: Supernus Pharmaceuticals against the median of its 20 peers (local-currency closes).

Supernus Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.37B$1.24B$1.19B$1.09B$901M
Revenue growth—+4%+9%+21%—
Gross profit$1.17B$1.02B$977M$919M$729M
EBITDA$633M$378M$298M$249M$230M
Net income$450M$210M$7.00M-$129M-$53.0M
Free cash flow$26.0M-$93.0M$7.00M-$308M-$9.00M
Capital expenditure$64.4M$67.0M$31.0M$53.0M$6.00M
Total debt$501M$351M$375M$283M$277M

Quarterly statements and history in the cockpit →

Supernus Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%MIRMLGND9995ABBOTINDIABIOCONGLANDBLTE6030870126Z0ORKA000999ALKEM000963688578MANE9926BANB6821SUPN6-month return →1-month return →
Up and to the right = strong over both horizons. Supernus Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%+300%20×40×60×LGND9995ABBOTINDIABIOCONGLAND603087APTX00099945066885786821SUPNRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Supernus Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%LGND9995ABBOTINDIAGLANDAPTX688578SUPNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Supernus Pharmaceuticals is the large dot.

Supernus Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (SUPN vs JAZZ vs AMRX vs NBIX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%8.0×6.2%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
Amneal Pharmaceuticals AMRX$7.62B+79%+9%16%19.2×17.2%
Neurocrine Biosciences NBIX$16.5B+5%+38%25%18.0×-1.5%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%

How Supernus Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Supernus Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSUPNPeer medianRank in peer set
1-month return-29.8%-0.3%2nd lowest of 21
6-month return-40.5%-0.4%2nd lowest of 20
Distance from 52-week high-51.5%-21.1%3rd lowest of 21
Revenue growth (TTM)+16.4%+11.6%7th highest of 17
Operating margin45.0%17.2%3rd highest of 18
Forward P/E8.0×24.4×2nd cheapest of 16
Growth the price implies (Req g, 7 yrs)6.2%0.9%5th most demanding of 11
Growth delivered (Del g)+13.9%+10.3%4th highest of 11
Hurdle (Req g minus delivered)-7.7 pp-5.6 pp6th least demanding of 11
EV / EBITDA9.8×23.3×2nd cheapest of 9
Net debt / EBITDA0.3×0.9×4th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%
RemeGen 9995.HKHong Kong$6.07B-28%+293%61%6.3×-6.8%+57.9%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a

Questions

Who are Supernus Pharmaceuticals's main competitors?
Named competitors: Jazz Pharmaceuticals (JAZZ), UCB (private or unlisted), Tris Pharma (private or unlisted), Amneal Pharmaceuticals (AMRX), Neurocrine Biosciences (NBIX), Takeda Pharmaceutical (4502.T). The cockpit's measured peer set (industry) also includes Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), RemeGen (9995.HK), Abbott India (ABBOTINDIA.NS), Biocon (BIOCON.NS), Gland Pharma (GLAND.NS).
Is Supernus Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 8.0× against a peer median of 24.4×, 2nd cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Supernus Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -40.5% against -0.4% for the median peer; over one year -35.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.